Recruiting trial = ; Ongoing trial = ; Funded by an IRDiRC member =

National clinical trial(s)

UNITED KINGDOM

Merseyside
LIVERPOOL

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase -GB

University of Liverpool

More details